Table 2 |
||||||
|
Biologic and nonbiologic DMARDs use 30 days before and after zoster vaccination (n = 514) |
||||||
|
30 days before vaccination |
Day of vaccination |
30 days after vaccination |
||||
|
n |
% |
n |
% |
n |
% |
|
|
|
||||||
|
Anti-TNF |
40 |
7.8 |
32 |
6.2 |
40 |
7.8 |
|
Etanercept |
18 |
3.5 |
12 |
2.3 |
18 |
3.5 |
|
Adalimumab |
11 |
2.1 |
9 |
1.8 |
11 |
2.1 |
|
Infliximab |
11 |
2.1 |
11 |
2.1 |
11 |
2.1 |
|
Other biologicsa |
4 |
0.8 |
4 |
0.8 |
4 |
0.8 |
|
Nonbiologic DMARDs |
||||||
|
Methotrexate |
52 |
10.1 |
34 |
6.6 |
45 |
8.8 |
|
Sulfasalazine |
16 |
3.1 |
13 |
2.5 |
16 |
3.1 |
|
Hydroxychloroquine |
26 |
5.1 |
17 |
3.3 |
25 |
4.9 |
|
Azathioprine |
1 |
0.2 |
1 |
0.2 |
1 |
0.2 |
|
Leflunomide |
3 |
0.6 |
3 |
0.6 |
3 |
0.6 |
|
Cyclosporine |
7 |
1.4 |
6 |
1.2 |
7 |
1.4 |
|
6-Mercaptopurine |
5 |
1.0 |
3 |
0.6 |
5 |
1.0 |
|
Oral glucocorticoid |
45 |
8.8 |
33 |
6.4 |
48 |
9.3 |
|
|
||||||
|
DMARDS, Disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; TNF, tumor necrosis factor. aThe categories (columns) are not exclusive (for example, a patient who used anti-TNF therapies continuously during the 60-day period would be counted in all three categories). bAbatacept, rituximab. |
||||||
|
Zhang et al. Arthritis Research & Therapy 2011 13:R174 doi:10.1186/ar3497 |
||||||
